Skip to main content
Top
Published in: Journal of Clinical Immunology 5/2020

01-07-2020 | Primary Immunodeficiency | Letter to Editor

The Konya Declaration for Patients with Primary Immunodeficiencies

Authors: László Maródi, The J Project Study Group

Published in: Journal of Clinical Immunology | Issue 5/2020

Login to get access

Excerpt

Every year since 2004 when the J Project was launched, the growing interest and activity of devoted clinicians and scientists in Eastern and Central Europe (ECE) and elsewhere and their efforts to make a difference in the care of patients with primary immunodeficiencies (PIDs) in their regions and countries are clear [1]. A few Central European countries have now progressed to such an extent that they are approaching the professional standards of Western Europe in terms of diagnosis, clinical care, and education [2]. By contrast, in some countries, particularly in Central Asia, PID diagnostics and care are no further advanced than they were in Central Europe 30–40 years ago. There are also remarkable regional differences in patient management, particularly in large countries, such as Russia. One of the biggest challenges facing us now is providing differential assistance to achieve advances throughout the whole J Project area (Fig. 1), which currently has markedly different levels of complex PID care. Maybe we can take inspiration from the Turkish dervishes. During their unique dancing performance, they hold one of their extended arms with the palm up, suggesting receiving, and the other arm with the palm facing downwards, suggesting giving. We must continually encourage those centers and groups with advanced levels of PID care to share their knowledge with those most in need of it.
Literature
1.
go back to reference Maródi L, J Project study group. Fifteen years of the J Project. J Clin Immunol. 2019;39:363–9.CrossRef Maródi L, J Project study group. Fifteen years of the J Project. J Clin Immunol. 2019;39:363–9.CrossRef
2.
go back to reference Erdős M, Uzvölgyi E, Nemes Z, Török O, Rákóczi E, Went-Sümegi N, et al. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat. 2005;25:506.CrossRef Erdős M, Uzvölgyi E, Nemes Z, Török O, Rákóczi E, Went-Sümegi N, et al. Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat. 2005;25:506.CrossRef
3.
go back to reference Sediva A, Bataneant M, Belevtsev M, Blaziene A, Ciznar P, Förster-Waldl E, et al. Primary immunodeficiencies in Central and Eastern Europe—the power of networking report on the activity of the Jeffrey Modell Foundation Centers Network in Central and Eastern Europe. Immunol Res. 2019;67:358–67.CrossRef Sediva A, Bataneant M, Belevtsev M, Blaziene A, Ciznar P, Förster-Waldl E, et al. Primary immunodeficiencies in Central and Eastern Europe—the power of networking report on the activity of the Jeffrey Modell Foundation Centers Network in Central and Eastern Europe. Immunol Res. 2019;67:358–67.CrossRef
4.
go back to reference Maródi L, Casanova JL. Primary immunodeficiency diseases: the J Project. Lancet. 2009;373:2179–81.CrossRef Maródi L, Casanova JL. Primary immunodeficiency diseases: the J Project. Lancet. 2009;373:2179–81.CrossRef
5.
go back to reference Maródi L. The J Project study group. The creation and progress of the J Project in Eastern and Central Europe. Ann N Y Acad Sci. 2011;1238:65–73.CrossRef Maródi L. The J Project study group. The creation and progress of the J Project in Eastern and Central Europe. Ann N Y Acad Sci. 2011;1238:65–73.CrossRef
6.
go back to reference Horváth Z, Rezaei N, Reisli I, Tuzankina I, Otarbayev N, Popandopulo P, et al. The spread of the J Project. J Clin Immunol. 2013;33:1037–42.CrossRef Horváth Z, Rezaei N, Reisli I, Tuzankina I, Otarbayev N, Popandopulo P, et al. The spread of the J Project. J Clin Immunol. 2013;33:1037–42.CrossRef
7.
go back to reference Soltész B, Tóth B, Shabashova N, Bondarenko A, Okada S, Cypowyj S, et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet. 2013;50:567–78.CrossRef Soltész B, Tóth B, Shabashova N, Bondarenko A, Okada S, Cypowyj S, et al. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. J Med Genet. 2013;50:567–78.CrossRef
Metadata
Title
The Konya Declaration for Patients with Primary Immunodeficiencies
Authors
László Maródi
The J Project Study Group
Publication date
01-07-2020
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2020
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-020-00797-4

Other articles of this Issue 5/2020

Journal of Clinical Immunology 5/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.